Siglimet 50 mg+1000 mg (Tablet)

Unit Price: ৳ 16.00 (5 x 6: ৳ 480.00)

Strip Price: ৳ 96.00

Medicine Details

Category	Details
Generic	Sitagliptin metformin hydrochloride
Company	Square pharmaceuticals plc
Also available as	Siglimet 50 mg tablet Siglimet xr 50 mg tablet Siglimet xr 50 mg tablet Siglimet xr 100 mg tablet

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Combines two antihyperglycemic agents with complementary mechanisms of action
Slows the inactivation of incretin hormones in patients with type 2 diabetes
Increases insulin release and decreases glucagon levels in a glucose-dependent manner
Decreases hepatic glucose production
Decreases intestinal absorption of glucose
Increases peripheral glucose uptake and utilization

Individualized dosage based on the patient's current regimen, effectiveness, and tolerability
Maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin
Twice daily with meals
Gradual dose escalation to reduce gastrointestinal side effects
Dose based on current regimen for patients not currently treated with metformin
Starting dose providing sitagliptin dosed as 50 mg twice daily and the dose of metformin already being taken for patients already treated with metformin
Administer extended-release tablet once daily with a meal preferably in the evening
Adjust dosing based on effectiveness and tolerability
Co-administration with insulin secretagogue or insulin may require lower doses to reduce the risk of hypoglycemia

Renal disease or renal dysfunction
Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma
History of a serious hypersensitivity reaction to this tablet or sitagliptin
Use caution in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials

Pregnancy Category B
Safety in pregnant women not known, should be used during pregnancy only if clearly needed
Caution should be exercised when administered to a nursing woman

Lactic acidosis can occur due to metformin accumulation
Regular monitoring of thyroid-stimulating hormone (TSH) levels is recommended in patients with hypothyroidism
Long-term treatment associated with a decrease in vitamin B12 serum levels
Monitoring of the vitamin B12 level is recommended
Do not use in patients with hepatic disease
Assess renal function before initiating and at least annually thereafter
Promptly discontinue if pancreatitis is suspected
Monitor hematologic parameters annually
Warn against excessive alcohol intake
May need to discontinue temporarily during periods of stress and decreased intake of fluids and food
Evaluate patients previously controlled on this tablet who develop laboratory abnormalities or clinical illness for evidence of ketoacidosis or lactic acidosis
May need lower dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia
There have been postmarketing reports of serious allergic and hypersensitivity reactions in patients treated with sitagliptin
No clinical studies establishing conclusive evidence of macrovascular risk reduction

Supportive measures in the event of an overdose
Employ clinical monitoring and institute supportive therapy as indicated by the patient's clinical status
Sitagliptin is modestly dialyzable
Hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected
Pancreatitis may occur in the context of a metformin overdose